Aclaris Therapeutics, Inc. ACRS 深 滬
等待開盤 06-25 09:30:00 美东时间
4.79
-0.130
-2.64%
華盛通- 最 高5.00
- 今 開4.93
- 成交量 148.24万股
- 最 低 4.705
- 昨 收 4.92
- 總市值 66.90万
- 52周最高 5.15
- 市盈率 靜 --
- 換手率 1.06%
- 52周最低 1.435
- 委 比 41.32%
- 總股本 0.00亿
- 歷史最高 33.88
- 量 比 0.72
- 振 幅 6.00%
- 歷史最低 0.5902
- 每 手 1
- 風險率 1.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SL Science Holding, Alamos Gold And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the S&P 500 futures falling around 0.1% on Monday. Shares of SL Science Holding Ltd (NASDAQ:SLBT) fell sharply in pre-market trading after the company reported its financial results for the full year ended Dec. 31. Net revenue fell by or 35% to around...
06-22 20:02
美股夜盘 | Sagtec Global Ltd. Class A涨92.93%，LEIFRAS Co涨37.26%
Akanda Corp涨-17.75%；BTQ Technologies涨-11.72%；Aclaris Therapeutics, Inc.涨-11.11%
06-22 08:05
This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday
Top Wall Street analysts begin coverage of Aclaris Therapeutics, Orion Group Holdings, and Take-Two Interactive.
06-03 21:13
Aclaris Therapeutics Q1 EPS $(0.15), Inline, Sales $1.996M Beat $1.322M Estimate
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 25 percent decrease over losses of $(0.12) per share from the same period last year.
05-07 21:23
Aclaris Q1 FY26 net loss widens to $19.8 million; revenue rises to $2 million
Aclaris Q1 FY26 net loss widens to $19.8 million; revenue rises to $2 million Aclaris Therapeutics posted a wider Q1 net loss of $19.8 million, or $0.15 per share, versus a $15.1 million loss a year earlier. Revenue rose 37.18% to $2 million, driven by higher royalties under Lilly and Sun Pharma lic
05-07 18:59
美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
Guggenheim Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $12
Guggenheim analyst Seamus Fernandez initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $12.
05-05 20:45
美股大行评级 | 瑞银：维持Visa"买入"评级！目标价从390美元升至410美元
今日重点评级关注：HC Wainwright & Co.：维持Protara Therapeutics"买入"评级，目标价从23美元升至27美元；BTIG：维持Black Diamond Therapeutic"买入"评级，目标价从10美元升至11美元
04-30 19:24
Aclaris Reports Positive ATI-052 Phase 1a Trial Results
Aclaris Therapeutics ( ($ACRS) ) has shared an update. On April 28, 2026, Aclar...
04-28 19:19
Aclaris Therapeutics to Reveal Clinical Update On Key Biologic And Oral Inhibitor Programs on April 28, 2026
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide the full results
04-28 04:50
